NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX)
Post# of 231
(Total Views: 296)
Posted On: 05/05/2021 5:26:37 PM
NetworkNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Secures Centralized IRB Approval for Acclaim-1 Clinical Trial
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced its receipt of centralized Institutional Review Board (“IRB”) approval of the clinical trial protocol for its upcoming Acclaim-1 clinical trial in non-small cell lung cancer (“NSCLC”). Acclaim-1 is an open-label, multi-center Phase 1/2 clinical trial that combines the company’s lead drug candidate, REQORSA(TM) immunogene therapy, with AstraZeneca’s Tagrisso(R) (osimertinib) in patients with late-stage NSCLC with mutated epidermal growth factor receptors (“EGFRs”), whose disease progressed after treatment with Tagrisso. “The purpose of IRB review is to assure that appropriate steps are taken to protect the rights and welfare of individuals participating as subjects in clinical research,” said Rodney Varner, president and CEO of Genprex. “With this centralized IRB approval, we have achieved another significant clinical milestone. We remain focused on completing our preparations for the Acclaim-1 clinical trial and look forward to its commencement.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced its receipt of centralized Institutional Review Board (“IRB”) approval of the clinical trial protocol for its upcoming Acclaim-1 clinical trial in non-small cell lung cancer (“NSCLC”). Acclaim-1 is an open-label, multi-center Phase 1/2 clinical trial that combines the company’s lead drug candidate, REQORSA(TM) immunogene therapy, with AstraZeneca’s Tagrisso(R) (osimertinib) in patients with late-stage NSCLC with mutated epidermal growth factor receptors (“EGFRs”), whose disease progressed after treatment with Tagrisso. “The purpose of IRB review is to assure that appropriate steps are taken to protect the rights and welfare of individuals participating as subjects in clinical research,” said Rodney Varner, president and CEO of Genprex. “With this centralized IRB approval, we have achieved another significant clinical milestone. We remain focused on completing our preparations for the Acclaim-1 clinical trial and look forward to its commencement.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)